BioPharmSignal logoBioPharmSignal

Biotech News

Ovid Therapeutics to Participate in Upcoming Investor Conferences

Ovid Therapeutics (OVID)Ovid TherapeuticsCompany update

Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company’s management will participate in three upcoming investor conferences:

Related news

AXSMAxsome2026-11-03 12:00 EST

Axsome Therapeutics to Participate in Upcoming Investor Conferences

IKTInhibikase Therapeutics2026-10-27 12:00 EST

Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026

ABOSAcumen Pharmaceuticals2026-09-02 20:00 EST

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

ANNXAnnexon, Inc.2026-09-02 12:00 EST

Annexon to Participate in Upcoming September Investor Conferences

NERVMinerva Neuroscience2026-08-28 12:00 EST

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

GANXGain Therapeutics2026-11-05 12:00 EST

Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences

MNOVMediciNova2026-09-08 10:00 EST

MediciNova to Participate in Two Investor Conferences in September

KTTAPasithea Therapeutics2026-09-03 20:05 EST

Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences

XENEXenon2026-11-03 21:01 EST

Xenon to Present at Upcoming Investor Conferences

ALKSAlkermes plc2026-11-03 21:00 EST

Alkermes to Present at Upcoming Investor Conferences

View all latest news

Ovid Therapeutics

Neurological Small-Molecule Company Ovid Therapeutics develops medicines for epilepsies and other intractable brain disorders. OV329 OV329 is a next-generation GABA aminotransferase inhibitor being developed for focal-onset seizures, tuberous sclerosis complex seizures, and infantile spasms. OV4071 OV4071 is an oral direct activator of...

Recent company news

OVIDOvid Therapeutics2026-11-05 13:00 EST

Ovid Therapeutics to Participate in Upcoming Investor Conferences

OVIDOvid Therapeutics2026-09-03 12:00 EST

Ovid Therapeutics to Participate in Upcoming Investor Conferences

OVIDOvid Therapeutics2026-08-13 12:30 EST

Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

OVIDOvid Therapeutics2026-07-08 11:00 EST

Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development

OVIDOvid Therapeutics2026-06-04 11:00 EST

Ovid Therapeutics to Participate in Upcoming Investor Conferences

Stock data

Close
2.58 USD
Market cap
447.94M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States